Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase

Retrovirology

Volumn 8, Issue , 2011, Pages

  Radzio, Jessica ^a,b   Sluis Cremer, Nicolas ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARAGINE; GLUTAMINE; ISOLEUCINE; LEUCINE; NEVIRAPINE; PHOSPHATE; PHOSPHOMONOESTER; PRIMER DNA; PRIMER RNA; PROTEIN P51; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; ZIDOVUDINE; PROTEIN SUBUNIT; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DNA TEMPLATE; ENZYME ACTIVITY; ENZYME STRUCTURE; MOLECULAR MODEL; MUTATION; MUTATIONAL ANALYSIS; PROTEIN CLEAVAGE; PROTEIN RNA BINDING; RIBONUCLEIC ACID TEMPLATE; RNA STRUCTURE; WILD TYPE; CELL LINE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN MOTIF;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID MOTIFS; CELL LINE; DNA MUTATIONAL ANALYSIS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; NEVIRAPINE; PROTEIN BINDING; PROTEIN SUBUNITS; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H;

EID: 80051855982     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-69     Document Type: Article

References (20)

1. De Clercq E. Antiretroviral drugs. Curr Opin Pharmacol 2010, 10:507-515. 10.1016/j.coph.2010.04.011, 20471318.
2. Goody RS, Müller B, Restle T. Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Lett 1991, 291:1-5. 10.1016/0014-5793(91)81089-Q, 1718777.
3. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256:1783-1790. 10.1126/science.1377403, 1377403.
4. di Marzo Veronese F, Copeland TD, DeVico AL, Rahman R, Oroszlan S, Gallo RC, Sarngadharan MG. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 1986, 231:1289-1291. 10.1126/science.2418504, 2418504.
5. Ehteshami M, Götte M. Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility. AIDS Rev 2008, 10:224-235.
6. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007, 4:e335. 10.1371/journal.pmed.0040335, 2100143, 18052601.
7. Radzio J, Yap SH, Tachedjian G, Sluis-Cremer N. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. AIDS 2010, 24:659-667. 10.1097/QAD.0b013e328336781d, 2874746, 20160634.
8. Ehteshami M, Beilhartz GL, Scarth BJ, Tchesnokov EP, McCormick S, Wynhoven B, Harrigan PR, Götte M. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem 2008, 283:22222-22232. 10.1074/jbc.M803521200, 2494928, 18547911.
9. Schuckmann MM, Marchand B, Hachiya A, Kodama EN, Kirby KA, Singh K, Sarafianos SG. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine. J Biol Chem 2010, 285:38700-38709. 10.1074/jbc.M110.153783, 20876531.
10. Biondi MJ, Beilhartz GL, McCormick S, Götte M. N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation. J Biol Chem 2010, 285:26966-26975. 10.1074/jbc.M110.105775, 20530477.
11. Nikolenko GN, Delviks-Frankenberry KA, Pathak VK. A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2010, 84:5238-5249. 10.1128/JVI.01545-09, 2863829, 20219933.
12. Sarafianos SG, Das K, Tantillo C, Clark AD, Ding J, Whitcomb JM, Boyer PL, Hughes SH, Arnold E. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J 2001, 20:1449-1461. 10.1093/emboj/20.6.1449, 145536, 11250910.
13. Nowotny M, Gaidamakov SA, Ghirlando R, Cerritelli SM, Crouch RJ, Yang W. Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol Cell 2007, 28:264-276. 10.1016/j.molcel.2007.08.015, 17964265.
14. Beilhartz GL, Wendeler M, Baichoo N, Rausch J, Le Grice S, Götte M. HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition. J Mol Biol 2009, 388:462-474. 10.1016/j.jmb.2009.03.025, 19289131.
15. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999, 4:35-43. 10.1016/S1097-2765(00)80185-9, 10445025.
16. Radzio J, Sluis-Cremer N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol Pharmacol 2008, 73:601-606.
17. Brehm JH, Mellors JW, Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 2008, 47:14020-14027. 10.1021/bi8014778, 2740331, 19067547.
18. Le Grice SF, Grüninger-Leitch F. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur J Biochem 1990, 187:307-314. 10.1111/j.1432-1033.1990.tb15306.x, 1688798.
19. Nissley DV, Radzio J, Ambrose Z, Sheen CW, Hamamouch N, Moore KL, Tachedjian G, Sluis-Cremer N. Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. Biochem J 2007, 404:151-157. 10.1042/BJ20061814, 1868834, 17286555.
20. Ambrose Z, Herman BD, Sheen CW, Zelina S, Moore KL, Tachedjian G, Nissley DV, Sluis-Cremer N. The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs. J Virol 2009, 83:3826-3833. 10.1128/JVI.01968-08, 2663283, 19193782.